Bowen M A, Bajorath J, Siadak A W, Modrell B, Malacko A R, Marquardt H, Nadler S G, Aruffo A
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA.
J Biol Chem. 1996 Jul 19;271(29):17390-6. doi: 10.1074/jbc.271.29.17390.
Activated leukocyte cell adhesion molecule (ALCAM) was recently identified as a ligand for CD6, a signaling receptor expressed on T cells, a subset of B cells, and some cells in the brain. Receptor-ligand binding assays, antibody blocking experiments, and examination of the tissue distribution of these two cell surface proteins suggest that CD6-ALCAM interactions play an important role in mediating the binding of thymocytes to thymic epithelial cells and of T cells to activated leukocytes. Presently, the details of CD6-ALCAM interactions and of signaling through CD6 are unknown. A series of truncated human ALCAM and CD6 immunoglobulin fusion proteins were produced and tested in different binding assays to analyze ALCAM-CD6 interactions in more detail. In this study, we report that the amino-terminal Ig-like domain of human ALCAM specifically binds to the third membrane-proximal scavenger receptor cysteine-rich (SRCR) domain of human CD6. Using thrombin-cleaved Ig fusion proteins containing single or multiple ALCAM or CD6 domains, we were able to determine that the stoichiometry of the interaction between the amino-terminal ALCAM domains and the membrane-proximal CD6 SRCR domain is 1:1. These results provide the first example of an Ig-like domain mediating an interaction with an SRCR domain.
活化白细胞细胞黏附分子(ALCAM)最近被确定为CD6的配体,CD6是一种信号受体,在T细胞、一部分B细胞以及大脑中的某些细胞上表达。受体-配体结合试验、抗体阻断实验以及对这两种细胞表面蛋白组织分布的研究表明,CD6-ALCAM相互作用在介导胸腺细胞与胸腺上皮细胞以及T细胞与活化白细胞的结合中起重要作用。目前,CD6-ALCAM相互作用的细节以及通过CD6的信号传导尚不清楚。我们制备了一系列截短的人ALCAM和CD6免疫球蛋白融合蛋白,并在不同的结合试验中进行测试,以更详细地分析ALCAM-CD6相互作用。在本研究中,我们报告人ALCAM的氨基末端免疫球蛋白样结构域特异性结合人CD6的第三个膜近端富含半胱氨酸的清道夫受体(SRCR)结构域。使用含有单个或多个ALCAM或CD6结构域的凝血酶切割的免疫球蛋白融合蛋白,我们能够确定氨基末端ALCAM结构域与膜近端CD6 SRCR结构域之间相互作用的化学计量比为1:1。这些结果提供了免疫球蛋白样结构域介导与SRCR结构域相互作用的首个实例。